A recently published study has found that the AstraZeneca vaccine does not protect against the "African variant" of nCoV-19, which is a worrying outcome, since the paper believes that we probably won't be able to manufacture a specifically targeted new vaccine for the rest of 2021.
CONCLUSIONS
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant.
A recently published study has found that the AstraZeneca vaccine does not protect against the "African variant" of nCoV-19, which is a worrying outcome, since the paper believes that we probably won't be able to manufacture a specifically targeted new vaccine for the rest of 2021.
https://www.nejm.org/doi/10.1056/NEJMoa2102214#.YFJIkr3ju7k.twitter